<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669383</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU eRIB#1845</org_study_id>
    <nct_id>NCT00669383</nct_id>
  </id_info>
  <brief_title>Rescue Antenatal Steroids and Pulmonary Function Tests in Preterm Infants</brief_title>
  <official_title>Rescue Antenatal Steroids and Lung Volumes in Preterm Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Lung Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One course of steroids given to a mother before a premature delivery helps the lungs of the
      premature infant and decreases breathing problems. One course of antenatal steroids is the
      standard of care for threatened premature deliveries. It is unclear as to how long the
      benefit of one course of steroids last. The most benefit to the baby's lungs seem to occur if
      the steroids are given at least 24 hours before but within 7 days of a premature delivery. It
      is difficult to predict the timing of a preterm delivery so deliveries often do not occur
      within this time period. We hypothesize that the benefits of the steroids to the lungs wear
      off if the steroids are given more than 14 days before a preterm delivery, and that in these
      circumstances an extra course of steroids will help the premature baby's lungs and the
      premature baby will have less breathing problems as shown by lung function testing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this randomized, blinded placebo controlled trial is to quantify and
      compare measurements of pulmonary function (including respiratory compliance and lung
      volumes/functional residual capacity) of hospitalized preterm infants whose mothers received
      an initial course of antenatal corticosteroids, remained undelivered after 14 days and at &lt;
      34 weeks of gestation, and were then randomized to either a rescue course of antenatal
      corticosteroids or to a rescue course of placebo. In addition, follow-up pulmonary function
      tests, clinical outcomes, growth parameters, and the neurodevelopmental outcome of these
      infants will be followed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurements of Functional Residual Capacity in Preterm Infants.</measure>
    <time_frame>Within first 72 hours after birth</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurements of Respiratory Compliance (Crs) in Preterm Infants.</measure>
    <time_frame>Within first 72 hours after birth</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FiO2</measure>
    <time_frame>During initial hospital stay and planned follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Respiratory Compliance</condition>
  <condition>Functional Residual Capacity</condition>
  <condition>Pulmonary Function Testing</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Betamethasone (Celestone) 12 mg intramuscular q 24 hours x 2 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dose intramuscular q 24 hours x 2 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>betamethasone</intervention_name>
    <description>12 mg IM q 24 hours x 2 doses</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Celestone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo IM q 24 hours x 2 doses</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than 14 days after first course of antenatal steroids;

          -  Less than 34 weeks of gestation;

          -  Identified by primary physician as continued risk for preterm delivery;

          -  Informed consent

        Exclusion Criteria:

          -  Major congenital anomalies

          -  Multiple gestation of triplets or greater

          -  Mother with insulin dependent diabetes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia McEvoy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>McEvoy C, Schilling D, Peters D, Tillotson C, Spitale P, Wallen L, Segel S, Bowling S, Gravett M, Durand M. Respiratory compliance in preterm infants after a single rescue course of antenatal steroids: a randomized controlled trial. Am J Obstet Gynecol. 2010 Jun;202(6):544.e1-9. doi: 10.1016/j.ajog.2010.01.038. Epub 2010 Mar 15.</citation>
    <PMID>20227053</PMID>
  </results_reference>
  <results_reference>
    <citation>McEvoy C, Schilling D, Spitale P, O'Malley J, Bowling S, Durand M. Pulmonary function and outcomes in infants randomized to a rescue course of antenatal steroids. Pediatr Pulmonol. 2017 Sep;52(9):1171-1178. doi: 10.1002/ppul.23711. Epub 2017 Apr 24.</citation>
    <PMID>28436580</PMID>
  </results_reference>
  <results_reference>
    <citation>Jordan BK, Schilling D, McEvoy CT. The window of improved neonatal respiratory compliance after rescue antenatal steroids. J Perinatol. 2018 Jul;38(7):828-833. doi: 10.1038/s41372-018-0124-9. Epub 2018 May 24.</citation>
    <PMID>29795314</PMID>
  </results_reference>
  <results_reference>
    <citation>Jordan BK, Schilling D, McEvoy CT. Pulmonary Function at Hospital Discharge in Preterm Infants Randomized to a Single Rescue Course of Antenatal Steroids. J Pediatr. 2017 Feb;181:62-66.e1. doi: 10.1016/j.jpeds.2016.10.022. Epub 2016 Nov 7.</citation>
    <PMID>27832835</PMID>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>April 28, 2008</study_first_submitted>
  <study_first_submitted_qc>April 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2008</study_first_posted>
  <results_first_submitted>October 15, 2018</results_first_submitted>
  <results_first_submitted_qc>October 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 22, 2019</results_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Cynthia McEvoy</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>premature delivery</keyword>
  <keyword>respiratory distress syndrome</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This randomized trial was conducted at Oregon Health and Science University in Portland, OR and at Sacred Heart Hospital in Pensacola, FL. Subjects were recruited from June 2001 to May 2007.</recruitment_details>
      <pre_assignment_details>Women who showed no further signs of preterm delivery after consent were not randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A (Betamethasone)</title>
          <description>Betamethasone (Celestone) 12 mg IM q 24 hours x 2 doses</description>
        </group>
        <group group_id="P2">
          <title>B (Placebo)</title>
          <description>Placebo dose IM q 24 hours x 2 doses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A (Betamethasone)</title>
          <description>Betamethasone (Celestone) 12 mg IM q 24 hours x 2 doses
betamethasone: 12 mg IM q 24 hours x 2 doses</description>
        </group>
        <group group_id="B2">
          <title>B (Placebo)</title>
          <description>Placebo dose IM q 24 hours x 2 doses
placebo: Placebo IM q 24 hours x 2 doses</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.9" spread="7.5"/>
                    <measurement group_id="B2" value="28.6" spread="6.4"/>
                    <measurement group_id="B3" value="27.7" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurements of Functional Residual Capacity in Preterm Infants.</title>
        <time_frame>Within first 72 hours after birth</time_frame>
        <population>Number of participants listed here is greater than the number listed in Participant flow as twin deliveries were not excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>A (Betamethasone)</title>
            <description>Betamethasone (Celestone) 12 mg IM q 24 hours x 2 doses</description>
          </group>
          <group group_id="O2">
            <title>B (Placebo)</title>
            <description>Placebo dose IM q 24 hours x 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Measurements of Functional Residual Capacity in Preterm Infants.</title>
          <population>Number of participants listed here is greater than the number listed in Participant flow as twin deliveries were not excluded.</population>
          <units>mL/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="8.8"/>
                    <measurement group_id="O2" value="22.0" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measurements of Respiratory Compliance (Crs) in Preterm Infants.</title>
        <time_frame>Within first 72 hours after birth</time_frame>
        <population>Number of participants listed here is greater than the number listed in Participant flow as twin deliveries were not excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>A (Betamethasone)</title>
            <description>Betamethasone (Celestone) 12 mg IM q 24 hours x 2 doses</description>
          </group>
          <group group_id="O2">
            <title>B (Placebo)</title>
            <description>Placebo dose IM q 24 hours x 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Measurements of Respiratory Compliance (Crs) in Preterm Infants.</title>
          <population>Number of participants listed here is greater than the number listed in Participant flow as twin deliveries were not excluded.</population>
          <units>mL/cm H2O/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="0.53"/>
                    <measurement group_id="O2" value="1.01" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FiO2</title>
        <time_frame>During initial hospital stay and planned follow-up</time_frame>
        <population>Number of participants is greater here as it includes all offspring, including twins.</population>
        <group_list>
          <group group_id="O1">
            <title>A (Betamethasone)</title>
            <description>Betamethasone (Celestone) 12 mg IM q 24 hours x 2 doses</description>
          </group>
          <group group_id="O2">
            <title>B (Placebo)</title>
            <description>Placebo dose IM q 24 hours x 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>FiO2</title>
          <population>Number of participants is greater here as it includes all offspring, including twins.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FiO2 greater or equal to 0.30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FiO2 greater or equal to 0.40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Number of participants listed here is greater than the number listed in participant flow as this section includes offspring and twins were included.</desc>
      <group_list>
        <group group_id="E1">
          <title>A (Betamethasone)</title>
          <description>Betamethasone (Celestone) 12 mg IM q 24 hours x 2 doses</description>
        </group>
        <group group_id="E2">
          <title>B (Placebo)</title>
          <description>Placebo dose IM q 24 hours x 2 doses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cindy McEvoy, MD</name_or_title>
      <organization>OHSU</organization>
      <phone>503-494-0223</phone>
      <email>mcevoyc@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

